Based on the anti-apoptotic role of MCL1, we reasoned that MCL1-inhibition might be most effective when combined with a pro-apoptotic drug, as previously demonstrated in PDX models of HER2-amplified breast cancer and TNBC treated with trastuzumab and docetaxel, respectively32. The gene discussed is ERBB2; the disease is breast carcinoma.